DEPO-PROVERA medroxyprogesterone acetate 150 mg/mL aqueous suspension injection vial Australia - English - Department of Health (Therapeutic Goods Administration)

depo-provera medroxyprogesterone acetate 150 mg/ml aqueous suspension injection vial

pfizer australia pty ltd - medroxyprogesterone acetate, quantity: 150 mg/ml - injection, suspension - excipient ingredients: propyl hydroxybenzoate; methyl hydroxybenzoate; water for injections; sodium chloride; macrogol 3350; polysorbate 80 - carcinoma: palliative treatment of recurrent and/or metastatic breast or renal cell cancer and of inoperable recurrent or metastatic endometrial carcinoma. endometriosis: for use in the treatment of visually proven (laparoscopy) endometriosis where the required end-point of treatment is pregnancy, or for the control of symptoms when surgery is contra- indicated or has been unsuccessful. contraception (ovulation suppression): for long-term prevention of pregnancy in women when administered at 3-month intervals. since loss of bone mineral density (bmd) may occur in pre-menopausal women who use depo-provera long-term (greater than 2 years), women should be assessed, before starting treatment for contraception or endometriosis, regarding the risk of osteoporosis. women under the age of 18 years may be at risk of failing to achieve their predicted peak bone mineral density (see warnings). the 50 mg/1ml vial is not approved for the indication of contraception (ovulation suppression). the injection, depo-provera 1

Depo-Provera 150 mg/ml Suspension for Injection Ireland - English - HPRA (Health Products Regulatory Authority)

depo-provera 150 mg/ml suspension for injection

pfizer healthcare ireland - medroxyprogesterone acetate - suspension for injection - 150 milligram(s)/millilitre - progestogens; medroxyprogesterone

Depo-Provera 150mg/1ml suspension for injection pre-filled syringes United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

depo-provera 150mg/1ml suspension for injection pre-filled syringes

pfizer ltd - medroxyprogesterone acetate - suspension for injection - 150mg/1ml

Depo-Provera New Zealand - English - Medsafe (Medicines Safety Authority)

depo-provera

pfizer new zealand limited - medroxyprogesterone acetate 150 mg/ml - injection (depot) - 150 mg/ml - active: medroxyprogesterone acetate 150 mg/ml excipient: hydrochloric acid macrogol 3350 methyl hydroxybenzoate polysorbate 80 propyl hydroxybenzoate sodium chloride sodium hydroxide - adjunctive and/or palliative treatment of recurrent and/or metastatic endometrial or renal carcinoma

DEPO-PROVERA 150 MGML Israel - English - Ministry of Health

depo-provera 150 mgml

pfizer pfe pharmaceuticals israel ltd - medroxyprogesterone acetate - suspension for injection - medroxyprogesterone acetate 150 mg/ml - medroxyprogesterone - medroxyprogesterone - for contraception where medically indicated and oral administration is inapplicable.

Depo-Provera 150 mg/ml inj. susp. i.m. pre-filled syr. Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

depo-provera 150 mg/ml inj. susp. i.m. pre-filled syr.

pfizer sa-nv - medroxyprogesterone acetate 150 mg/ml - suspension for injection - 150 mg/ml - medroxyprogesterone acetate 150 mg/ml - medroxyprogesterone

Depo-Provera 150 mg/ml inj. susp. i.m. vial Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

depo-provera 150 mg/ml inj. susp. i.m. vial

pfizer sa-nv - medroxyprogesterone acetate 150 mg/ml - suspension for injection - 150 mg/ml - medroxyprogesterone acetate 150 mg/ml - medroxyprogesterone

Depo-Provera 150mg/1ml suspension for injection vials United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

depo-provera 150mg/1ml suspension for injection vials

pfizer ltd - medroxyprogesterone acetate - suspension for injection - 150mg/1ml

DEPO-PROVERA medroxyprogesterone acetate 150 mg/1 mL suspension for injection pre-filled syringe Australia - English - Department of Health (Therapeutic Goods Administration)

depo-provera medroxyprogesterone acetate 150 mg/1 ml suspension for injection pre-filled syringe

pfizer australia pty ltd - medroxyprogesterone acetate, quantity: 150 mg/ml - injection, suspension - excipient ingredients: propyl hydroxybenzoate; methyl hydroxybenzoate; water for injections; sodium chloride; macrogol 3350; polysorbate 80 - carcinoma: palliative treatment of recurrent and/or metastatic breast or renal cell cancer and of inoperable recurrent or metastatic endometrial carcinoma. endometriosis: for use in the treatment of visually proven (laparoscopy) endometriosis where the required end-point of treatment is pregnancy, or for the control of symptoms when surgery is contra- indicated or has been unsuccessful. contraception (ovulation suppression): for long-term prevention of pregnancy in women when administered at 3-month intervals. since loss of bone mineral density (bmd) may occur in pre-menopausal women who use depo-provera long-term (greater than 2 years), women should be assessed, before starting treatment for contraception or endometriosis, regarding the risk of osteoporosis. women under the age of 18 years may be at risk of failing to achieve their predicted peak bone mineral density (see warnings). the 50 mg/1ml vial is not approved for the indication of contraception (ovulation suppression). the injection, depo-provera 150 mg/1ml, should be used for contraception.

DEPO-PROVERA 150 MG/ML, SUSPENSION FOR INJECTION, Ireland - English - HPRA (Health Products Regulatory Authority)

depo-provera 150 mg/ml, suspension for injection,

pharmacia ireland - medroxyprogesterone acetate - suspension for injection - 150